Beam Therapeutics (BEAM) Operating Leases (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Operating Leases data on file, last reported at $135.8 million in Q1 2026.

• Quarterly Operating Leases fell 6.26% year-over-year to $135.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $135.8 million (down 6.26% YoY) and the FY2025 annual result came in at $139.8 million, down 5.54% from the prior year.
• Operating Leases declined to $135.8 million in Q1 2026 per BEAM's latest filing, from $139.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $168.6 million in Q4 2022 and bottomed at $135.8 million in Q1 2026.
• The 5-year median for Operating Leases is $152.6 million (2024), against an average of $152.4 million.
• The widest annual swing landed in 2022, when Operating Leases gained 25.08%; it then slipped 7.48% in 2024.
• Tracing BEAM's Operating Leases over 5 years: stood at $168.6 million in 2022, then slipped by 5.17% to $159.9 million in 2023, then dropped by 7.48% to $148.0 million in 2024, then fell by 5.54% to $139.8 million in 2025, then slipped by 2.8% to $135.8 million in 2026.
• Per Business Quant, the three latest BEAM Operating Leases figures stand at $135.8 million (Q1 2026), $139.8 million (Q4 2025), and $138.7 million (Q3 2025).

Peer Comparison